FindMyRecallSubscribe
Class II: temporary or reversible health riskOngoing

Glenmark Pharmaceuticals Naproxen Tablets Recall

Naproxen Tablets, USP 250mg, 100-count bottle, Rx Only, Manufactured by: Glenmark Pharm…

Glenmark Pharmaceuticals Inc., USA · Mahwah, NJ

Risk level
Class II
Reported by FDA
Dec 6, 2023
Recall ID
D-0124-2024
Check your lot numberHow we source this data

Summary

Glenmark Pharmaceuticals recalled Naproxen Tablets starting Nov 7, 2023. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0124-2024 on Dec 6, 2023. Reason: Labeling: Label Mix-Up-Indomethacin bottles may be labeled as Naproxen. Status: Ongoing.

Why it was recalled

Labeling: Label Mix-Up-Indomethacin bottles may be labeled as Naproxen

Product description

Naproxen Tablets, USP 250mg, 100-count bottle, Rx Only, Manufactured by: Glenmark Pharmaceuticals Ltd. Colvale-Bardez, Goa 403513, India, Manufactured for: Glenmark Pharmaceuticals Inc., USA Mahwah, NJ 07430, NDC 68462-188-01.

Lot numbers, UPCs & expiration codes

Lot# 19231903; Exp 4/2025 Lot# 19231858; Exp 4/2025 Lot# 19231881; Exp 4/2025 Lot# 19233484: Exp 8/2025 Lot# 19233490; Exp 8/2025

Where it was sold

Nationwide

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0124-2024
Classification
Class II
Status
Ongoing
Recall initiated
Nov 7, 2023
FDA report date
Dec 6, 2023
Recall type
Voluntary: Firm initiated
Recalling firm
Glenmark Pharmaceuticals Inc., USA

Original FDA data

Every field from FDA enforcement report D-0124-2024, exactly as published.

Show all FDA fields
City
Mahwah
State
NJ
Status
Ongoing
Country
United States
Event ID
93368
Address
750 Corporate Dr
Code information
Lot# 19231903; Exp 4/2025 Lot# 19231858; Exp 4/2025 Lot# 19231881; Exp 4/2025 Lot# 19233484: Exp 8/2025 Lot# 19233490; Exp 8/2025
Postal code
07430-2009
Report date
Dec 6, 2023
Product type
Drugs
Recall number
D-0124-2024
Classification
Class II
Recalling firm
Glenmark Pharmaceuticals Inc., USA
Reason for recall
Labeling: Label Mix-Up-Indomethacin bottles may be labeled as Naproxen
Voluntary / mandated
Voluntary: Firm initiated
Product description
Naproxen Tablets, USP 250mg, 100-count bottle, Rx Only, Manufactured by: Glenmark Pharmaceuticals Ltd. Colvale-Bardez, Goa 403513, India, Manufactured for: Glenmark Pharmaceuticals Inc., USA Mahwah, NJ 07430, NDC 68462-188-01.
Distribution pattern
Nationwide
Recall initiation date
Nov 7, 2023
Initial firm notification
Letter
Center classification date
Nov 27, 2023

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0124-2024, published Dec 6, 2023. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls